| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2008, p. 2250-2252, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01025-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
,
Pablo E. Tomatis,2,
María A. Mussi,1
Fernando Pasteran,3
Alejandro M. Viale,1
Adriana S. Limansky,1 and
Alejandro J. Vila2*
Departamento de Microbiología,1 Departamento de Química Biológica, Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Buenos Aires, Argentina,2 Servicio Antimicrobianos, Departamento Bacteriología, Instituto Nacional de Enfermedades Infecciosas—ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina3
Received 3 August 2007/ Returned for modification 12 October 2007/ Accepted 15 March 2008
A detailed biochemical characterization of the Pseudomonas aeruginosa VIM-11 metallo-β-lactamase (MβL) is reported. The only substitution differentiating VIM-11 from VIM-2 (N165S) promoted a slightly improved catalytic efficiency of the former on 3 out of 12 substrates, notably the bulky cephalosporins. Thus, MβL-mediated resistance also may be modulated by remote mutations.
Published ahead of print on 24 March 2008.
Supplemental material for this article may be found at http://aac.asm.org/.
These authors contributed equally to this work.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |